Dr. Esserman on the I-SPY 2 Trial in Breast Cancer
Laura Esserman, MD, MBA
Published Online: Wednesday, April 10, 2013
Laura Esserman, MD, MBA, Professor, University of California, San Francisco, comments on the findings from the I-SPY 1 trial and the basis for the I-SPY 2 trial in patients with breast cancer.
From the I-SPY 1 trial, researchers and physicians found out how to get all biomarkers off of a single core and that it was possible to work together to share data and bio-specimens. Not only did pathologic complete response translate into a better outcome for survival and recurrence, it also proved to be a much better signal for different disease subsets.
Rather than analyze subsets retrospectively, Esserman says, physicians should sort out data from the beginning to know for whom and in which subset new drugs might work.
The US Supreme Court’s landmark decision last June, mandating that an individual’s genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.
The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.